After yesterday’s spike in shares of most high-growth software companies, the market has cooled down quite a bit and is giving the high growth portfolio the opportunity to add to some positions where there have been positive developments and negative share price reaction. Much of yesterday’s spike was a function of what I think was…
I made some changes in the High Growth portfolio this morning. I sold half of the Datadog position after its recent run. I think the shares are likely to consolidate after a 66% run in the past month. I decided to redeploy the funds to other positions that I believe have a grade potential for…
We added to 3 positions in the high growth portfolio and added a new company as well. These positions essentially replaced the sale we made yesterday of Nebius which raised about $78k. The purchases were as follows: 1) 250 shares of Tempus AI @ $50.39-purchase cost of $12,605 and weight of 0.55%. The Tempus purchase is obviously…
Before proceeding to the review of AppLovin and Axon earnings a brief detour into the land of algo trading. Today, shares of Klaviyo fell by 32%. The issue was not one of demand: overall revenue growth and the guidance for revenue growth were strong. Revenue growth was 28% a beat of a bit less than…
The stock market, after making several daily records, is under pressure today. Hi-growth software stocks have fallen and ServiceNow shares along with shares of IBM have seen significant drawdowns. I strongly felt that the sell-off in Service Now was not a reasonable interpretation of the quarter just reported and added to the position. And overall, I used the proceeds…
Alphotographic/iStock via Getty Images What’s new at Axon: Operationally business has seen strong positive trends; the stock price has become compressed It has been 18 months since I last wrote about Axon (AXON) for SA. After rising to almost $900 a share before a poorly received earnings report, the shares have fallen by no less than 59% since…
I made some changes in the high growth portfolio this morning. I decided to sell 500 more shares of Nebius shortly after the opening and I got a fill at $167.29. There is an old Wall St. saying about trees not growing to heaven. Nebius is up 95% so far this year. I have presented my model…
Axon’s run: What should readers do now? It has been little more than a year since I first recommended Axon (AXON) shares. So far in 2024, the shares are up 68% and they have consistently been making new all-time highs. The quintessential pattern of a momentum growth stock. Much of the share price increase has come since the latest earnings…
Summary Axon, a company that provides solutions to the public safety sector, is experiencing significant growth due to high demand for its products and a successful subscription/recurring revenue model.Despite a recent share price drop due to poorly received guidance, the company’s estimated revenues over the next four quarters are predicted to be $1.7 billion, with…